

Clinical trials of oral anticoagulant

TrialResults-center www.trialresultscenter.org

1 atrial fibrillation

Trial	Treatments	Patients	Trials design and methods
oral anticoagulant vs placebo			
EAFT , 1993 n=225/214 follow-up: 2.3 years	Oral anticoagulation standard dose(target INR 3.0 (2.5-4.0)) the choice of anticoagulant type was free but most physicians choose coumarin derivatives. versus placebo	Patient with non rheumatic AF and recent TIA or minor ischaemic stroke(secondary prevention).	Parallel groups Open

More details and results :

- antithrombotics for atrial fibrillation in secondary prevention of thromboembolic events at <http://www.trialresultscenter.org/go-Q392>

References

EAFT, 1993:

Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet. 1993 Nov 20;342(8882):1255-62 [[7901582](#)]